RBC Capital Maintains Brookdale Senior Living(BKD.US) With Buy Rating, Cuts Target Price to $8
RBC Capital Sticks to Their Buy Rating for Brookdale Senior Living (BKD)
BofA Securities Maintains Brookdale Senior Living(BKD.US) With Sell Rating, Cuts Target Price to $5.5
Brookdale Senior Living Analyst Ratings
Jefferies Initiates Brookdale Senior Living(BKD.US) With Buy Rating, Announces Target Price $8
Brookdale Senior Living Is Maintained at Outperform by Macquarie
Brookdale Senior Living Price Target Maintained With a $8.00/Share by Macquarie
Macquarie Maintains Brookdale Senior Living(BKD.US) With Buy Rating
RBC Capital Maintains Brookdale Senior Living(BKD.US) With Buy Rating, Maintains Target Price $9
Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Brookdale Senior Living (BKD) and Vertex Pharmaceuticals (VRTX)
Brookdale Senior Living Cut to Underperform From Neutral by B of A Securities
Brookdale Senior Living Analyst Ratings
BofA Securities Downgrades Brookdale Senior Living(BKD.US) to Sell Rating, Cuts Target Price to $6
Macquarie Maintains Brookdale Senior Living(BKD.US) With Buy Rating
Macquarie Reaffirms Their Buy Rating on Brookdale Senior Living (BKD)
BofA Securities Maintains Brookdale Senior Living(BKD.US) With Hold Rating, Maintains Target Price $7.75
Brookdale Senior Living Analyst Ratings
RBC Capital Reiterates Outperform on Brookdale Senior Living, Maintains $9 Price Target
Analysts Offer Insights on Healthcare Companies: Merus (MRUS), Brookdale Senior Living (BKD) and Arrowhead Pharmaceuticals (ARWR)
Brookdale Senior Living Analyst Ratings